BRCA1/2 mutation non-carriers with HRD features can also benefit from PARP inhibitors, [118, 121, 141] thus, a major challenge has been to identify HRD tumors beyond gBRCAm. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.